<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04077671</url>
  </required_header>
  <id_info>
    <org_study_id>CLI-06467AA1-01</org_study_id>
    <secondary_id>2018-001724-19</secondary_id>
    <nct_id>NCT04077671</nct_id>
  </id_info>
  <brief_title>CHF6467 SAD and MAD in Patients With Diabetic Foot Ulcer</brief_title>
  <official_title>A Randomised, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profiles of CHF6467 After Single and Repeated Ascending Doses in Subjects With Diabetic Neurophatic Foot Ulcers (DFU).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiesi Farmaceutici S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Comac Medical</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Chiesi Farmaceutici S.p.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the safety and tolerability of single and multiple days' topical dosing with&#xD;
      CHF6467 in subjects with diabetic foot ulcer (DFU).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This first in human study is designed to investigate the tolerability, safety,&#xD;
      pharmacokinetics and preliminarily pharmacodynamics following topical administration of&#xD;
      single and multiple ascending doses of CHF6467 in subjects diagnosed with diabetic foot ulcer&#xD;
      (DFU).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 17, 2018</start_date>
  <completion_date type="Actual">January 7, 2021</completion_date>
  <primary_completion_date type="Actual">January 7, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>SAD - Single Ascending Dose &amp; MAD - Multiple Ascending Dose</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Double Blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment Emergent Adverse Events (TEAEs)</measure>
    <time_frame>SAD: From Day 1 up to Day 28; MAD: From Day 1 up to Day 84;</time_frame>
    <description>During the SAD and the MAD, the number of events and the number and percentage of subjects experiencing TEAEs, treatment emergent ADRs, serious TEAEs, non-serious TEAEs, severe TEAEs, TEAEs leading to discontinuation of study drug and TEAEs leading to death will be presented by treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: AUC0-72h after single administration</measure>
    <time_frame>SAD: Serial of timepoints until 72 hours post dose</time_frame>
    <description>During the SAD: Dose proportionality of CHF6467 for AUC0-72h, and classical PK parameters will be calculated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic: Ulcer area after multiple administration</measure>
    <time_frame>MAD: From Day 1 to Days 4, 7, 10, 14, 17, 21, 24, 28, 31, 35, 38, 42, 45, 49, 52, 56, 59, 63, 66, 70, 73, 77, 80 and 84</time_frame>
    <description>MAD: Ulcer area measurements expressend in cm2 over time after multiple administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: AUC0 to infinit after multiple administration</measure>
    <time_frame>MAD: Serial of timepoints at Day 1, Day 2, Day 4, Day 7, Day 10, Day 13, Day 14, Day 21 and Day 28</time_frame>
    <description>During the MAD: Dose proportionality of CHF6467 for AUC 0 to infinit, and classical PK parameters will be calculated</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">93</enrollment>
  <condition>Diabetic Neuropathic Foot Ulcers</condition>
  <arm_group>
    <arm_group_label>SAD - Cohort A - CHF6467 0.3 µg/mm2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort A: will be administered with CHF6467 0.3 µg/mm2 ulcer area as single dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD - Cohort B - CHF6467 1 µg/mm2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort B: will be administered with 1 µg/mm2 ulcer area as single dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD - Cohort C - CHF6467 3 µg/mm2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort C: will be administered with 3 µg/mm2 ulcer area as single dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD - Cohort D - CHF6467 6 µg/mm2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort D: will be administered with 6 µg/mm2 ulcer area as single dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD - Cohort E - CHF6467 0.3 or 1 µg/mm2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort E: will be administered with 0.3 or 1 µg/mm2 ulcer area (total daily dose) as multiple dose (14 days). The dose will be selected based on the SAD results.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD - Cohort F - CHF6467 1 or 3 µg/mm2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort F: will be administered with 1 or 3 µg/mm2 ulcer area (total daily dose) as multiple dose (14 days). The dose will be selected based on the SAD results.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CHF6467 active</intervention_name>
    <description>CHF6467, is mutated form of the human Nerve Growth Factor (NGF).</description>
    <arm_group_label>MAD - Cohort E - CHF6467 0.3 or 1 µg/mm2</arm_group_label>
    <arm_group_label>MAD - Cohort F - CHF6467 1 or 3 µg/mm2</arm_group_label>
    <arm_group_label>SAD - Cohort A - CHF6467 0.3 µg/mm2</arm_group_label>
    <arm_group_label>SAD - Cohort B - CHF6467 1 µg/mm2</arm_group_label>
    <arm_group_label>SAD - Cohort C - CHF6467 3 µg/mm2</arm_group_label>
    <arm_group_label>SAD - Cohort D - CHF6467 6 µg/mm2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject's written informed consent obtained prior to any study-related procedure;&#xD;
&#xD;
          2. Male or female subject, aged 18 - 80 years (extremes inclusive), diagnosed with Type I&#xD;
             or Type II diabetes mellitus, with glycosylated haemoglobin (HbA1c) ≤ 10%.&#xD;
&#xD;
          3. Female subjects of non-childbearing potential (WONCBP):&#xD;
&#xD;
               -  they must report surgical sterilization (performed at least 6 months prior to&#xD;
                  screening), or&#xD;
&#xD;
               -  menopause (must have had no regular menstrual bleeding for at least one year&#xD;
                  prior to screening, age ≥ 45 years and FSH at screening ≥ 40 mIU/ml).&#xD;
&#xD;
          4. Female subject with childbearing potential (WOCBP): they must be using one or more of&#xD;
             the following reliable methods of contraception during the study period and at least&#xD;
             within 90 days after the last study drug administration:&#xD;
&#xD;
               1. Placement of an intrauterine device (IUD) or intrauterine system (IUS).&#xD;
&#xD;
               2. Hormonal contraception (implantable, patch, oral).&#xD;
&#xD;
               3. Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical&#xD;
                  vaults/caps) with spermicidal foam/gel/film/cream/suppository.&#xD;
&#xD;
               4. Male Partner sterilization (with the appropriate post-vasectomy documentation of&#xD;
                  the absence of sperm in the ejaculate).&#xD;
&#xD;
          5. Male subjects; they must be using two effective methods of contraception during the&#xD;
             entire study period and not donate sperm within 90 days after the last study drug&#xD;
             administration.&#xD;
&#xD;
          6. Presence of at least one diabetic foot ulcer meeting the following criteria:&#xD;
&#xD;
               1. Diagnosed as a full-thickness, neuropathic DFU, located at or distal to the&#xD;
                  malleolus (excluding ulcers between the toes but including those of the heel)&#xD;
&#xD;
               2. SAD: Present for 6 weeks to 12 months, and of 3 - 5 cm2 in area following sharp&#xD;
                  debridement, confirmed at screening.&#xD;
&#xD;
                  MAD: Present for 6 weeks to 12 months, and of 3 - 6 cm2 in area following sharp&#xD;
                  debridement confirmed at screening, and of 2-5 cm2 after the 2 weeks run-in&#xD;
                  period with an area reduction compared to screening &lt;50%.&#xD;
&#xD;
               3. A minimum 1 cm margin between the qualifying study ulcer and any other ulcers on&#xD;
                  the specified foot.&#xD;
&#xD;
               4. SAD: Ulcer must have a depth ≥ 5 mm at some point in its area and be graded 1A&#xD;
                  according to &quot;The University of Texas Staging System for Diabetic Foot Ulcers&quot;&#xD;
                  (22), with no capsule, tendon or bone exposed and no tunnelling, undermining, or&#xD;
                  sinus tracts, after the initial sharp debridement, confirmed at screening.&#xD;
&#xD;
             MAD: Ulcer must have a depth ≥ 5 mm at some point in its area and be graded 1A or 2A&#xD;
             according to &quot;The University of Texas Staging System for Diabetic Foot Ulcers&quot; (22),&#xD;
             after the initial sharp debridement, confirmed at screening.&#xD;
&#xD;
          7. Subject must be able to hold the target ulcer in such a position and orientation that&#xD;
             the study medication can be applied without significant loss of substance through&#xD;
             run-off, until the dressing has been applied.&#xD;
&#xD;
          8. Adequate vascular perfusion of the affected limb demonstrated within 30 days prior to&#xD;
             screening, as defined by at least one of the following:&#xD;
&#xD;
               1. Ankle-Brachial Index (ABI) ≥ 0.9 and ≤ 1.2, confirmed by transcutaneous oxygen&#xD;
                  partial pressure (TcPO2) &gt;50 mmHg&#xD;
&#xD;
               2. Toe pressure (plethysmography) &gt;50 mmHg&#xD;
&#xD;
               3. Doppler ultrasound (biphasic or triphasic waveforms) at least on two vessels at&#xD;
                  the ankle consistent with adequate blood flow to the affected extremity, as&#xD;
                  determined by SoC.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. For females only: pregnant or lactating female subject, confirmed by a positive serum&#xD;
             pregnancy test at screening and a urine test performed on Day -1.&#xD;
&#xD;
          2. Subject with:&#xD;
&#xD;
               1. Ulcer(s) accompanied by infected cellulitis, osteomyelitis, or clinical signs or&#xD;
                  symptoms of infection confirmed by a cultural exam made on the material taken off&#xD;
                  from the ulcer according to the technique described in the guidelines for&#xD;
                  diagnosis and management of diabetic foot infections of the Infectious Diseases&#xD;
                  Society of the Americas (IDSA) (19).&#xD;
&#xD;
               2. Gangrene or necrosis on any part of the affected limb.&#xD;
&#xD;
               3. Active or chronic Charcot's foot on the study limb.&#xD;
&#xD;
               4. Planned vascular surgery, angioplasty or thrombolysis or previous&#xD;
                  revascularization procedure performed within 1 month prior to enrolment.&#xD;
&#xD;
               5. SD only: Ulcers involving exposure of tendon, bone, or joint capsule (It is&#xD;
                  acceptable to have ulcers extending through the dermis and into subcutaneous&#xD;
                  tissue with presence of granulation tissue).&#xD;
&#xD;
               6. Ulcer(s) of non-diabetic aetiology.&#xD;
&#xD;
               7. Previous Lisfranc or Chopart's amputations on the same target foot.&#xD;
&#xD;
               8. Actual or recent (3 weeks) antibiotic therapy for any reason.&#xD;
&#xD;
               9. Bedridden subjects or subjects with a life expectancy less than one year.&#xD;
&#xD;
          3. Use of any growth factor therapy in the 3 months prior to screening.&#xD;
&#xD;
          4. History of malignancy in the 5 years prior to screening or those with a strong family&#xD;
             history of cancer (e.g. familial cancer disorders), with the exception of squamous&#xD;
             cell or basal cell carcinoma of the skin that has been definitively treated.&#xD;
&#xD;
          5. Clinically significant cardiovascular, pulmonary, renal, endocrine, hepatic,&#xD;
             neurological, psychiatric, immunological, gastrointestinal, haematological or&#xD;
             metabolic disease that is, in the opinion of the Investigator, not stabilised or may&#xD;
             otherwise impact subject safety or study results (in cases of doubt, the Sponsor's&#xD;
             Clinical Research Physician should be consulted).&#xD;
&#xD;
          6. Subject undergoing haemodialysis or peritoneal dialysis or with chronic renal&#xD;
             insufficiency (plasma creatinine &gt; 2 mg/dl).&#xD;
&#xD;
          7. Subject with significantly abnormal key laboratory parameters interfering with the&#xD;
             safety of the patient according to the PI judgement.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Iliya Lozev, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Comac Medical</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Comac Medical Ltd.</name>
      <address>
        <city>Sofia</city>
        <zip>1618</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>March 28, 2019</study_first_submitted>
  <study_first_submitted_qc>September 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 4, 2019</study_first_posted>
  <last_update_submitted>February 3, 2021</last_update_submitted>
  <last_update_submitted_qc>February 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DFU</keyword>
  <keyword>Diabetic Foot Ulcers</keyword>
  <keyword>Diabetic Neuropathic Foot Ulcers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Foot Ulcer</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

